Araris Biotech AG and Taiho Pharmaceutical Collaborate to Advance ADCs With Araris' Unique Linker-conjugation Technology
Thursday, November 09, 2023
Araris Biotech AG, a Swiss company specializing in oncology, has recently entered into a collaborative agreement with Taiho Pharmaceutical Co., Ltd., a Japanese pharmaceutical company focused on oncology research and development. According to the agreement, Araris will leverage its proprietary linker-conjugation platform to create novel antibody drug conjugates (ADCs) targeting specific objectives provided by Taiho.
The ADCs developed by Araris will undergo further examination and evaluation by Taiho. While the financial terms of the collaboration remain undisclosed, Dragan Grabulovski, Ph.D., the acting CEO of Araris, expressed pride in the collaboration and looks forward to jointly developing next-generation ADCs with enhanced efficacy and tolerability.
Philipp Spycher, Ph.D., Araris' chief scientific officer, emphasized the potential of their linker-payload platform in producing ADCs with exceptional properties. This collaboration positions Araris as an attractive partner for pharmaceutical companies interested in advancing oncology research.
Source: globenewswire.com
